# Vision — Automated Regulatory Filing Module

**Agent:** `L1-vision-statement-generator` · **Phase:** 0 (Idea → Vision) · **Correlation ID:** `C885C23C-949E-440C-8B0E-04FDD166A559`
**Inputs:** [idea-brief.json](idea-brief.json) · [market-analysis.md](market-analysis.md) · [regulatory-feasibility.md](regulatory-feasibility.md)
**Viability score:** 8/10 (PASS, threshold ≥7) — see [quality-gates.md](../quality-gates.md)

## Problem

Executives and legal/compliance teams at publicly traded companies on Computershare's EquatePlus platform file securities transaction disclosures (starting with SEC Form 4) through a manual, error-prone process. SEC Form 4 must be filed within 2 business days of a trade; PRD-stated baselines put current on-time/error-free performance at ~70% (unverified — carried from PRD.txt §8, not an independently confirmed measurement; see [idea-brief.json](idea-brief.json) provenance note). Missed or erroneous filings carry financial penalty, legal, and reputational risk for both the individual filer and the company.

## Target users

- **Corporate Executive** (insider, files under Section 16) — wants compliance handled with minimal manual effort and clear status visibility.
- **Legal & Compliance Officer** — wants real-time visibility across all executives' filings, low-friction review/approval, and a defensible audit trail.

## Solution direction

Auto-generate a pre-filled SEC Form 4 within 5 minutes of a transaction executing in EquatePlus, stream it to legal/compliance for review, edit, and approval, and track it through submission — with full audit logging and proactive deadline-risk notification. SEC Form 4 is the v1 form; the architecture should not preclude Form 5 / Form 144 later (FR11).

## North-star metric

**% of regulatory filings submitted within the required deadline, error-free.** PRD-stated target: 98% (from ~70% baseline). Both figures are unverified planning inputs (see idea-brief.json) — the Product Lead should confirm them against real EquatePlus/compliance data as an early Requirements-phase action, not treat them as committed OKRs yet.

Supporting metrics (also unverified baselines, same caveat): average transaction-to-submission time (target 30 min, from a stated 24h baseline), manual data-entry errors/month (target 0, from a stated baseline of 5), executive adoption rate (target 90% within 6 months).

## Roadmap outline

1. **Core filing pipeline** — detection, generation, validation, review/approval, audit log (maps to Epic E1).
2. **Visibility & notifications** — streaming to legal, notification system, compliance dashboard, export (maps to Epic E2).
3. **Resilience & extensibility** — sync-error handling, bulk/rapid-trade handling, additional forms, third-party analytics (maps to Epic E3).

## Regulatory Posture

*(Carried forward per zero-tolerance rule — see [regulatory-feasibility.md](regulatory-feasibility.md) for full detail.)*

No Red (blocking) findings against US SEC Section 16 regulation for a v1 scoped to Form 4. **Two Amber findings must be resolved no later than Phase 4 (Design), not before Vision approval:**

1. **EDGAR submission mechanism is undetermined** — whether this module submits directly to SEC EDGAR (Regulation S-T electronic filing) or hands a completed, approved form to an existing manual filing-agent process. This materially affects HLD scope for E1.F3 (submission step) and must be resolved with Legal & Compliance before HLD is drafted.
2. **Deadline-risk notification (FR3/AC3) must key off EDGAR's actual same-day cutoff (5:30 p.m. ET)**, not the raw 2-business-day calendar deadline, or the "at risk" alert can be silently wrong.

Additional non-blocking notes carried forward: reviewer-inaction (a Legal/Compliance Officer not acting promptly) is a distinct risk path from data-sync failure and should get its own escalation handling, not be folded into E3.F1; the applicability of a 7-year retention period to issuer (vs. broker-dealer) records should be confirmed by counsel rather than assumed.

## Scope carried forward

Out of scope for this product (from PRD, reaffirmed): manual transaction entry, non-EquatePlus platform integration, non-US regulatory forms.

## Open commercial questions (not resolved by this phase)

Market sizing (TAM/SAM/SOM) is currently TBD — no licensed market-research figure was available, and this module's most defensible sizing is likely bottom-up from Computershare's own EquatePlus issuer/Section 16-officer base rather than a general market estimate. Pricing/packaging is also undetermined; recommend positioning as an EquatePlus subscription value-add pending commercial input. Neither blocks Requirements Elaboration but both should be tracked as open decisions.

---

## 👤 Human Gate — Product Lead Review

**This is a stop point.** Per the blueprint, Requirements Elaboration (Phase 1) does not begin until:
1. The Product Lead reviews this vision statement and the underlying viability score, and
2. Records an explicit approval (the downstream `L1-requirements-elicitor` step is designed to refuse to run without a recorded approval).

**Decision needed from you:**
- Approve this vision as-is and proceed to Phase 1 (Requirements → Impact → Dependency)?
- Approve with changes (note them and I'll revise before proceeding)?
- Do you want the two open items (baseline-metric provenance, EDGAR submission mechanism) resolved now, or tracked as open risks into later phases as currently written?
